Tax Inversion

Shire, AbbVie join forces for $55B

Shire, AbbVie join forces for $55B

By

The deal includes a $1.6-billion fee if AbbVie tries to walk away.

Shire asks AbbVie for more money

Shire asks AbbVie for more money

By

Shire and AbbVie's courtship has entered round five. A deal would offer AbbVie tax relief, and possibly make it an acquisition target.

Abbott pairs generics with tax benefit

Abbott and Mylan are setting up a generics business. The all-stock deal will give some branded generics a new home and offer Abbott a tax benefit that will increase over time.

Salix heads to Ireland

Salix heads to Ireland

By

Salix Pharmaceuticals joins the tax-inversion migration by purchasing Cosmo Technologies.

Email Newsletters